Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Neoplasm
88%
Malignant Neoplasm
52%
Targeted Therapy
51%
Epidermal Growth Factor Receptor
42%
Diagnosis
30%
Molecular Diagnosis
25%
Biopsy
20%
Intraabdominal Hypertension
20%
Abdominal Compartment Syndrome
20%
Chronic Myelomonocytic Leukemia
20%
ALK Inhibitor
20%
Anaplastic Lymphoma Kinase
20%
Clinical Decision Making
20%
Resistance Mutation
20%
Somatics
20%
Immunohistochemistry
20%
Decision Making
15%
Prevalence
14%
Next Generation Sequencing
12%
Oncologist
10%
Cancer Diagnostics
10%
Molecular Profiling
10%
Cancer
10%
Exon
9%
Progression Free Survival
9%
Pathologist
8%
Molecular Pathology
8%
Molecular Diagnostics
8%
In Vitro
6%
Clinical Trial
6%
Gene Fusion
6%
Language Processing
5%
Overall Survival
5%
Abdominal Pressure
5%
Pancreatitis
5%
Tumor Cell
5%
Personalized Medicine
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
40%
Mutational Profile
40%
Molecular Tumor Board
40%
Groningen
28%
University Medical Centre
28%
Targeted Therapy
28%
EGFR mutation
22%
Intra-abdominal Hypertension
20%
Pattern-based
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Diagnostic Challenge
20%
Mixed Cancer
20%
Survival Trends
20%
Abdominal Compartment Syndrome
20%
STING1
20%
Routine Testing
20%
Molecular Diagnostics
20%
Chronic Myeloid Leukemia
20%
Pan-TRK Immunohistochemistry
20%
Automatic Data Processing
20%
Cancer Cases
15%
Genetic Modification
15%
Confidence Interval
13%
Malignancy
10%
Profiling Techniques
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Rare Variants
10%
Tumor-infiltrating
10%
Molecular Profiling
10%
Oncogenic mutations
10%
PIK3CA
10%
Cancer Diagnostics
10%
Metagenomic Next-generation Sequencing (mNGS)
10%
Initial Diagnosis
10%
Non-small Cell Lung Cancer Patients
8%
L858R
8%
Non-target-site Resistance
8%
Exon 19 Deletion
7%
Clinical Trials
7%
Stimulator of Interferon Genes Pathways
6%
Actionable Variants
5%
Treatment Outcome
5%
Molecular Profile
5%
EGFR Testing
5%
EGFR Inhibitors
5%
Kinase Inhibitor Therapy
5%
Netherlands
5%
Median Progression-free Survival
5%
Pancreatitis
5%
Intra-abdominal Pressure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
80%
Neoplasm
62%
Epidermal Growth Factor Receptor
28%
Abdominal Compartment Syndrome
20%
Intraabdominal Hypertension
20%
Trametinib
20%
Anaplastic Lymphoma Kinase
20%
Anaplastic Lymphoma Kinase Inhibitor
20%
Dabrafenib
20%
Osimertinib
20%
Prevalence
14%
Malignant Neoplasm
12%
Progression Free Survival
8%
Pancreatitis
5%
Overall Survival
5%
